Literature DB >> 21070081

CyberKnife stereotactic ablative radiotherapy for lung tumors.

Iris C Gibbs1, Billy W Loo.   

Abstract

Stereotactic ablative radiotherapy (SABR) has emerged as a promising treatment for early stage non-small cell lung cancer, particularly for patients unable to tolerate surgical resection. High rates of local tumor control have been demonstrated with acceptable toxicity and the practical advantage of a short course of treatment. The CyberKnife image-guided robotic radiosurgery system has unique technical characteristics that make it well suited for SABR of tumors that move with breathing, including lung tumors. We review the qualities of the CyberKnife platform for lung tumor SABR, and provide a summary of clinical data using this system specifically.

Entities:  

Mesh:

Year:  2010        PMID: 21070081     DOI: 10.1177/153303461000900607

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  15 in total

1.  LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

Authors:  S Adebahr; S Collette; E Shash; M Lambrecht; C Le Pechoux; C Faivre-Finn; D De Ruysscher; H Peulen; J Belderbos; R Dziadziuszko; C Fink; M Guckenberger; C Hurkmans; U Nestle
Journal:  Br J Radiol       Date:  2015-04-15       Impact factor: 3.039

Review 2.  Extracranial stereotactic body radiotherapy. Review of main SBRT features and indications in primary tumors.

Authors:  Carmen Rubio; Rosa Morera; Ovidio Hernando; Thomas Leroy; S Eric Lartigau
Journal:  Rep Pract Oncol Radiother       Date:  2013-11-01

3.  Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer.

Authors:  Sana D Karam; Zachary D Horne; Robert L Hong; Nimrah Baig; Gregory J Gagnon; Don McRae; David Duhamel; Nadim M Nasr
Journal:  Lung Cancer (Auckl)       Date:  2013-08-06

4.  Evaluation of a cone beam computed tomography geometry for image guided small animal irradiation.

Authors:  Yidong Yang; Michael Armour; Ken Kang-Hsin Wang; Nishant Gandhi; Iulian Iordachita; Jeffrey Siewerdsen; John Wong
Journal:  Phys Med Biol       Date:  2015-06-17       Impact factor: 3.609

5.  Radiation-Induced Secondary Cancer Risk Assessment in Patients With Lung Cancer After Stereotactic Body Radiotherapy Using the CyberKnife M6 System With Lung-Optimized Treatment.

Authors:  Pei-Ju Chao; I-Hsing Tsai; Chun-Chieh Huang; Chih-Hsueh Lin; Chin-Shiuh Shieh; Yang-Wei Hsieh; Pei-Ying Yang; Hsiao-Fei Lee; Tsair-Fwu Lee
Journal:  Front Bioeng Biotechnol       Date:  2020-05-07

6.  Hypofractionated stereotactic body radiation therapy for elderly patients with stage IIB-IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities.

Authors:  Sana D Karam; Zachary D Horne; Robert L Hong; Don McRae; David Duhamel; Nadim M Nasr
Journal:  Lung Cancer (Auckl)       Date:  2014-10-03

7.  The effect of CyberKnife therapy on pulmonary function tests used for treating non-small cell lung cancer: a retrospective, observational cohort pilot study.

Authors:  Rishi Agarwal; Paramveer Saluja; Angela Pham; Karen Ledbetter; Sukhveer Bains; Seema Varghese; John Clements; Young H Kim
Journal:  Cancer Manag Res       Date:  2012-10-10       Impact factor: 3.989

8.  Efficacy study of CyberKnife stereotactic radiosurgery combined with CIK cell immunotherapy for advanced refractory lung cancer.

Authors:  Yuan-Yuan Wang; Yi-Shan Wang; Tao Liu; Ke Yang; Gui-Qing Yang; Han-Chen Liu; Shan-Shan Wang; Jia-Lin Yang
Journal:  Exp Ther Med       Date:  2012-11-19       Impact factor: 2.447

9.  Successful treatment of non-small cell lung tumor with 15 lesions by CyberKnife radiosurgery: A case report.

Authors:  Guiqing Yang; Mingguang Li; Yishan Wang; Yuanyuan Wang; Xiaoxu Liu
Journal:  Exp Ther Med       Date:  2013-06-28       Impact factor: 2.447

Review 10.  The potential role of respiratory motion management and image guidance in the reduction of severe toxicities following stereotactic ablative radiation therapy for patients with centrally located early stage non-small cell lung cancer or lung metastases.

Authors:  Alexander Chi; Nam Phong Nguyen; Ritsuko Komaki
Journal:  Front Oncol       Date:  2014-06-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.